Browsing Tag
delpacibart braxlosiran
2 posts
Dyne’s FORCE RNA therapy reversed muscle damage in mice, and its first FSHD trial is now cleared
DYNE-302 enters clinical development after FDA clearance as Dyne expands its FORCE pipeline following a $431.4 million equity raise.
Why Novartis’ $12bn Avidity bet suddenly looks more interesting after new del-brax data
Find out how Novartis AG’s del-brax data could strengthen its $12bn Avidity Biosciences bet and rare muscle disease strategy.